UDC 616.155.392-006.44-06:616-005.6+616-005.1:615.277.3+616-084

The long-term use of tyrosine kinase inhibitors (TKIs) has converted chronic myeloid leukemia (CML) into a largely controllable chronic disease. This therapeutic success has shifted clinical priorities toward complications that may compromise survivorship, particularly the concurrent risks of thrombosis and bleeding arising from both disease biology and treatment-related, off-target effects.